Table 2.
Characteristics associated with SARS-CoV-2 antibody prevalence in persons who inject drugs and their partners
| Characteristic | Number of total participants (N = 309) |
Percentage SARS-CoV-2 antibody positive | Odds Ratio (OR) (95% CI) | P-value | Adjusted OR (aOR) (95% CI)* | P-value |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Female | 119 | 37.2 | Ref | Ref | Ref | Ref |
| Male | 190 | 28.4 | 0.67 (0.59, 0.91) | 0.006 | 0.68 (0.51–0.95) | 0.010 |
| Age (years) | ||||||
| 18–35 | 135 | 29.0 | Ref | Ref | Ref | Ref |
| 36–74 | 174 | 33.3 | 1.23 (0.94, 1.61) | 0.14 | 1.23 (0.93–1.64) | 0.153 |
| Relationship Status | ||||||
| Single | 99 | 27.7 | Ref | Ref | Ref | Ref |
| Married or partnered | 87 | 29.5 | 1.09 (0.77, 1.53) | 0.620 | 1.14 (0.80–1.62) | 0.48 |
| Divorced or separated | 123 | 36.7 | 1.50 (1.09, 2.08) | 0.013 | 1.47 (1.05–2.06) | 0.024 |
| Education Level | ||||||
| No formal education | 20 | 32.8 | Ref | Ref | ||
| Primary level | 177 | 30.3 | 0.89 (0.51, 1.59) | 0.683 | ||
| Secondary level | 96 | 31.7 | 0.95 (0.53, 1.74) | 0.866 | ||
| Tertiary level | 16 | 41.0 | 1.43 (0.67, 3.29) | 0.403 | ||
| Region of Enrollment | ||||||
| Nairobi | 171 | 34.7 | Ref | Ref | Ref | Ref |
| Coast | 138 | 27.9 | 0.73 (0.55, 0.95) | 0.021 | 0.72 (0.54, 0.95) | 0.022 |
| HIV Status | ||||||
| Living with HIV | 151 | 30.6 | 0.93 (0.72, 1.23) | 0.631 | ||
| Living without HIV | 158 | 32.0 | Ref | Ref | ||
| Injected in the Past Week | ||||||
| Yes | 250 | 31.2 | 0.98 (0.70, 1.39) | 0.928 | ||
| No | 59 | 31.6 | Ref | Ref | ||
| Currently Taking Methadone | ||||||
| Yes | 124 | 28.8 | 0.81 (0.62, 1.07) | 0.135 | 0.91(0.68–1.21) | 0.506 |
| No | 185 | 32.8 | Ref | Ref | Ref | Ref |
| High-Risk Exposure in Past 2 Weeks | ||||||
| Yes | 9 | 31.0 | 0.99 (0.42, 2.14) | 0.977 | ||
| No | 300 | 31.3 | Ref | Ref | ||
| Any Sexual or Injecting Partners Diagnosed with COVID-19 | ||||||
| Yes | 15 | 46.9 | 1.99 (0.97, 4.04) | 0.057 | 2.21 (1.06–4.58) | 0.032 |
| No | 294 | 30.8 | Ref | Ref | Ref | Ref |
| Any Housing Partners Diagnosed with COVID-19 | ||||||
| Yes | 8 | 23.5 | 0.67 (0.28, 1.43) | 0.325 | ||
| No | 301 | 31.6 | Ref | Ref | ||
CI confidence interval
*Includes all variables associated with non-suppression in univariate analysis at p < 0.20